Lutetium-177 (Lu-177) Market
完整報告名稱與涵蓋範圍
Lutetium-177 (Lu-177) Market Size, Share & Trends Analysis Report, By Product Type (Non-Carrier-Added (n.c.a.) Lu-177, Carrier-Added (c.a.) Lu-177), By Application (Prostate Cancer (PSMA-Targeted Therapy), Neuroendocrine Tumors (SSTR-Targeted Therapy), Other Oncology Indications in Development), By End User (Hospitals and Nuclear Medicine Centers, Radiopharmaceutical Manufacturers, Research Institutes), By Region, and Segment Forecasts, 2026-2035
報告摘要
The lutetium-177 market comprises the production and supply of the beta-emitting radionuclide Lu-177 in carrier-added and non-carrier-added grades, plus the finished Lu-177-labelled radioligand therapies administered in nuclear medicine departments. Both the isotope-supply layer and the therapeutic product layer are quantified, with supply chain analysis spanning enriched ytterbium-176 and lutetium-176 targets, reactor irradiation, radiochemical separation and just-in-time distribution.
Commercial demand has been transformed by approved radioligand therapies for metastatic castration-resistant prostate cancer and gastroenteropancreatic neuroendocrine tumors, with label expansions into earlier lines of therapy multiplying eligible patients. Because Lu-177 decays with a roughly 6.6-day half-life, treatment centers depend on tightly scheduled production, and shortages during reactor outages have pushed sponsors toward dual sourcing and toward n.c.a. material that avoids long-lived Lu-177m impurities and simplifies waste management. Investment is flowing into new reactor capacity, accelerator-based alternatives, enriched target supply and regional radiopharmacy networks able to deliver patient-ready doses.
Europe and North America generate most consumption today, with Germany, the Netherlands, Belgium and the United States anchoring production, while Japan, China, South Korea and Australia are building domestic supply and expanding treatment center capacity. Competition spans specialist isotope producers, reactor operators and pharmaceutical groups that combine isotope supply with proprietary ligand portfolios.
The InsightAce study delivers revenue forecasts in US$ across all product type, application and end user and regional segments for 2026-2035, alongside segment-level trend analysis, competitive landscape assessment and detailed company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Lutetium-177 (Lu-177) Market Snapshot
Chapter 4. Global Lutetium-177 (Lu-177) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Product Type Estimates & Trend Analysis
5.1. Product Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Product Type:
5.2.1. Non-Carrier-Added (n.c.a.) Lu-177
5.2.2. Carrier-Added (c.a.) Lu-177
Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. Application & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Application:
6.2.1. Prostate Cancer (PSMA-Targeted Therapy)
6.2.2. Neuroendocrine Tumors (SSTR-Targeted Therapy)
6.2.3. Other Oncology Indications in Development
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. End User & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
7.2.1. Hospitals and Nuclear Medicine Centers
7.2.2. Radiopharmaceutical Manufacturers
7.2.3. Research Institutes
Chapter 8. Lutetium-177 (Lu-177) Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. Novartis AG
10.2. ITM Isotope Technologies Munich SE
10.3. Curium
10.4. Eckert & Ziegler SE
10.5. SHINE Technologies, LLC
10.6. NorthStar Medical Radioisotopes, LLC
10.7. Isotopia Molecular Imaging Ltd.
10.8. NRG (PALLAS)
10.9. IRE ELiT
10.10. Eli Lilly and Company (POINT Biopharma)
10.11. Lantheus Holdings, Inc.
10.12. Bayer AG
10.13. Telix Pharmaceuticals Ltd.
10.14. China Isotope & Radiation Corporation
圖表清單 List of Tables & Figures
Table 1. Global Lutetium-177 (Lu-177) Revenue Forecast by Product Type, 2026-2035 (US$ Mn)
Figure 1. Global Lutetium-177 (Lu-177) Market Snapshot, 2026 & 2035
Table 2. Global Lutetium-177 (Lu-177) Revenue Forecast by Application, 2026-2035 (US$ Mn)
Figure 2. Global Lutetium-177 (Lu-177) Market Share by Application, 2026 & 2035
Table 3. Global Lutetium-177 (Lu-177) Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 3. Lu-177 Supply Chain from Enriched Targets to Patient-Ready Doses
Table 4. North America Lutetium-177 (Lu-177) Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Eligible Patient Growth from Radioligand Therapy Label Expansions, 2026-2035
Table 5. Europe Lutetium-177 (Lu-177) Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Lutetium-177 (Lu-177) Growth Opportunity Analysis
Table 6. Asia Pacific Lutetium-177 (Lu-177) Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Carrier-Added Versus n.c.a. Lu-177 Adoption by Region
Table 7. Latin America and Middle East & Africa Lutetium-177 (Lu-177) Revenue Forecast, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Lutetium-177 (Lu-177) Market Participants
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們